Luteolin/ ZnO nanoparticles attenuate neuroinflammation associated with diabetes via regulating MicroRNA ‐124 by targeting C/ EBPA
Environmental Toxicology · 2023
DOI: 10.1002/tox.23903 ↗Kurz gefasst
Fachartikel in der Zeitschrift Environmental Toxicology, 2023. Verfasst von Enas M Moustafa und 2 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Biology, National Center for Radiation Research and Technology, Egyptian Atomic Energy Authority, Cairo, Egypt. Hauptthemen laut MEDLINE: Diabetes Mellitus, Experimental, Insulins, MicroRNAs, Neuroinflammatory Diseases. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 64 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Objective
The most prevalent brain‐specific microRNA, MicroRNA‐124, exhibits anti‐inflammatory properties. Luteolin nano‐formulation with Zn oxide in the form of L/ZnO NPs may boost anti‐diabetic properties; however, its beneficial effect on miRNAs is yet unknown in diabetes. The effectiveness of L/ZnONPs supplements in preventing diabetic neurodegeneration by modulating inflammatory responses in a diabetic model was investigated.
Methods
A diabetic rat model was induced by a high‐fat diet and streptozotocin (30 mg/kg I.P.). Plasma glucose, insulin, and HOMR‐IR levels, as well as cytokines, lipid peroxidation, GSH/GSSG, and glucose transporter 1, were determined along with the tight junction proteins occludin (OCLN) and zona occludens 1 (ZO‐1). Moreover, the expressions of brain CCAAT/enhancer‐binding protein (C/EBPA mRNA), miR‐124, glial fibrillary acidic protein (GFAP), and NF‐kBp65 were measured alongside the histological investigation.
Results
The results revealed that L/ZnO NPs were able to diminish lipid peroxidation, increase the activity of antioxidant enzymes, and reduce inflammation under oxidative stress. Consequently, it was able to reduce hyperglycemia, elevate insulin levels, and improve insulin resistance. Besides, L/ZnO NPs upregulate miR‐124, reduce C/EBPA mRNA, increase BCl‐2, and inhibit apoptosis. The results indicate that diabetes raises BBB permeability via tight junction protein decline, which is restored following L/ZnO NPs treatment. Luteolin/ZnO NPs regulate miR‐124 and microglia polarization by targeting C/EBPA and are expected to alleviate inflammatory injury via modulation of the redox‐sensitive signal transduction pathways. Luteolin/ZnO NPs have a novel target for the protection of the BBB and the prevention of neurological complications in diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Radiation Biology, National Center for Radiation Research and Technology, Egyptian Atomic Energy Authority, Cairo, Egypt.
- Health radiation research, National Center for Radiation Research and Technology, Egyptian Atomic Energy Authority, Cairo, Egypt.
ORCID-Profile: Enas M Moustafa, Fatma S M Moawed
Zitieren
APA
Moustafa, E. M., Moawed, F. S. M., & Elmaghraby, D. F. (2023). Luteolin/ ZnO nanoparticles attenuate neuroinflammation associated with diabetes via regulating MicroRNA ‐124 by targeting C/ EBPA. Environmental Toxicology. https://doi.org/10.1002/tox.23903
Vancouver
Moustafa EM, Moawed FSM, Elmaghraby DF. Luteolin/ ZnO nanoparticles attenuate neuroinflammation associated with diabetes via regulating MicroRNA ‐124 by targeting C/ EBPA. Environmental Toxicology. 2023. doi:10.1002/tox.23903
BibTeX
@article{Moustafa2023,
author = {Moustafa, Enas M and Moawed, Fatma S M and Elmaghraby, Dina F},
title = {Luteolin/ ZnO nanoparticles attenuate neuroinflammation associated with diabetes via regulating MicroRNA ‐124 by targeting C/ EBPA},
journal = {Environmental Toxicology},
year = {2023},
doi = {10.1002/tox.23903}
}
EUVIMED